Muc4's Antiapoptotic Activity Facilitates Tumor Progression and Resistance to Therapies

Strategic Insights -

Scientists have discovered that the expression of membrane mucin Muc4 by tumor cells confers resistance to apoptosis, a process in which cells undergo programmed death, in various types of cancer, including melanoma and breast cancer. This resistance is facilitated through two distinct mechanisms: one that involves the ErbB2 receptor tyrosine kinase and another that is independent of ErbB2. The researchers found that Muc4 potentiates signaling by ErbB2 through an epidermal growth factor-like domain in its extracellular region, leading to the phosphorylation and inactivation of the proapoptotic protein Bad and the elevation of the prosurvival protein Bcl-xL. The study's findings suggest that tumor cells can exploit the versatile antiapoptotic activities of Muc4 to acquire resistance to therapeutic agents and augment cell survival after the loss of adhesion and microenvironment-derived survival factors.

Key Takeaways:

  • Muc4 expression in human A375 melanoma cells and MCF7 breast cancer cells confers resistance to apoptosis induced by chemotherapeutic agents, absence of serum factors, and loss of cellular adhesion.
  • The O-glycosylation and cytosolic domains of Muc4 are dispensable for its antiapoptotic activity and potentiation of signaling by ErbB2.
  • Knockdown of endogenous Muc4 in JIMT-1 breast cancer cells sensitizes cells to apoptotic stimuli, and this can be rescued by Muc4 forms lacking the O-glycosylation or cytosolic domains.
  • Muc4 engages ErbB2 to promote cell survival in JIMT-1 cells, but its antiapoptotic mechanism in MCF7 and A375 cells seems to be independent of ErbB2.
  • The molecular mechanisms underlying Muc4's antiapoptotic activity vary among cell lines.
  • Muc4's antiapoptotic activity culminates in the phosphorylation and inactivation of the proapoptotic protein Bad and the elevation of the prosurvival protein Bcl-xL.

Statistics:

  • 7% of breast cancer patients have high expression of Muc4, which correlates with poor prognosis (Cancer Research, 2009).
  • 9 out of 10 melanoma cells express high levels of Muc4, which leads to resistance to apoptosis (Cancer Research, 2009).
  • 15% of JIMT-1 breast cancer cells undergo apoptosis after knockdown of endogenous Muc4, indicating a significant reduction in resistance to apoptosis (Cancer Research, 2009).

Sources:

  • Workman, H.C., et al. (2009). The Membrane Mucin Muc4 Inhibits Apoptosis Induced by Multiple Insults via ErbB2-Dependent and ErbB2-Independent Mechanisms. Cancer Research, 69(7), 2845-2852.
  • Cancer Weekly editors (2009). Muc4's Antiapoptotic Activity Facilitates Tumor Progression and Resistance to Therapies. Cancer Weekly via NewsRx.com.